Tissue microarray analysis of connexin expression and its prognostic significance in human breast cancer

Cancer Letters

Volumn 255, Issue 2, 2007, Pages 284-294

  Conklin, Chris ^a   Huntsman, David ^b   Yorida, Erika ^b   Makretsov, Nikita ^b   Turbin, Dmitry ^b   Bechberger, John F ^a   Sin, Wun Chey ^a   Naus, Christian C ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Breast cancer; Connexin; Gap junctions; Tissue microarrays

Indexed keywords

CONNEXIN 26; CONNEXIN 32; CONNEXIN 43; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GAP JUNCTION PROTEIN; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53; THYROID HORMONE RECEPTOR BETA; TUMOR MARKER;

ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER GRADING; CANCER MORTALITY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CELL COMMUNICATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RELIABILITY; TISSUE MICROARRAY; TUMOR VOLUME;

ANIMALS; BREAST NEOPLASMS; CONNEXINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LYMPH NODES; NEOPLASM STAGING; PROGNOSIS; RATS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 34547948714     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.05.001     Document Type: Article

References (47)

1. Lacey Jr. J.W., Deveso S.S., and Briton L.A. Recent trends in breast cancer incidence and mortality. Environ. Mol. Mutag. 39 (2002) 82-88
2. Rogers C.E., Loveday R.L., Drew P.J., and Greenman J. Molecular prognostic indicators in breast cancer. Eur. J. Surg. Oncol. 28 (2002) 467-478
3. Lamy P., Pujol P., Thezenas S., Kramar A., Rouanet P., Guilleux F., and Grener J. Progesterone receptor quantification as a strong prognostic determinant in postmenopausal breast cancer women under tamoxifen therapy. Breast Cancer Res. Treat. 76 (2002) 65-71
4. Chebil G., Bendahl P.O., Idvall I., and Ferno M. Comparison of immunohistochemical and biochemical assay of steroid receptors in primary breast cancer - clinical associations and reasons for discrepancies. Acta Oncol. 42 (2003) 719-725
5. Andronas M., Dlay S.S., and Sherbet G.V. Oestrogen and progesterone receptor expression influences DNA ploidy and the proliferation potential of breast cancer cells. Anticancer Res. 23 (2003) 3029-3039
6. Bouzubar N., Walker K.J., Griffiths K., Ellis I.O., Elston C.W., Robertson J.F., Blamey R.W., and Nicholson R.L. Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br. J. Cancer 59 (1989) 943-949
7. Trosko J.E., and Chang C.C. Mechanism of up-regulated gap junctional intercellular communication during chemoprevention and chemotherapy of cancer. Mutat. Res. 480-481 (2001) 219-229
8. Trosko J.E., and Ruch R.J. Gap junctions as targets for cancer chemoprevention and chemotherapy. Curr. Drug Targets 3 (2002) 465-482
9. Yamasaki H., and Naus C.C. Role of connexin genes in growth control. Carcinogenesis 17 (1996) 1199-1213
10. Carystinos G.D., Bier A., and Batist G. The role of connexin-mediated cell-cell communication in breast cancer metastasis. J. Mammary Gland Biol. Neoplasia 6 (2001) 431-440
11. Naus C.C. Gap junctions and tumor progression. Can. J. Physiol. Pharmacol. 80 (2002) 136-141
12. Hirschi K.K., Xu F.F., Tsukamoto T., and Sager R. Gap junction genes Cx26 and Cx43 individually suppress the cancer phenotype of human mammary carcinoma cells and restore differentiation potential. Cell Growth Differ. 7 (1996) 861-870
13. Qin H., Shao Q., Curtis H., Galipeau J., Belliveau D., Wang T., Alaoui-Jamali M.A., and Laird D.W. Retroviral delivery of connexin genes to human breast tumor cells inhibits in vivo tumor growth by a mechanism that is independent of significant gap junctional intercellular communication. J. Biol. Chem. 277 (2002) 29132-29138
14. Jamieson S., Going J.J., D'Arcy R., and George W.D. Expression of gap junction proteins connexin 26 and connexin 43 in normal human breast and in breast tumours. J. Pathol. 184 (1998) 37-43
15. Wilgenbus K.K., Kirkpatrick C.J., Knuechel R., Willecke K., and Traub O. Expression of Cx26, Cx32 and Cx43 gap junction proteins in normal and neoplastic tissues. Int. J. Cancer 51 (1992) 522-529
16. Elston C.W., and Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 19 (1991) 403-410
17. Parker R.L., Huntsman D.G., Lesack D.W., Cupples J.B., Grant D.R., Akbari M., and Gilks C.B. Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am. J. Clin. Pathol. 117 (2002) 723-728
18. Laird D.W., Jordan K., Thomas T., Qin H., Fistouris P., and Shao Q. Comparative analysis and application of fluorescent protein-tagged connexins. Microsc. Res. Tech. 52 (2001) 263-272
19. Liu C.L., Prapong W., Natkuman Y., Alizadeh A., Montgomery K., Gilks C.B., and van de Rijn M. Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. Am. J. Pathol. 161 (2002) 1557-1564
20. Makretsov N.A., Huntsman D.G., Nielsen T.O., Yorida E., Peacock M., Cheang M.C., Dunn S.E., Hayes M., van de Rijn M., Bajdik C., and Gilks C.B. Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. Clin. Cancer Res. 10 (2004) 6143-6151
21. Nagy J.I., Li X., Rempel J., Stelmack G., Patel D., Staines W.A., Yasumura T., and Rash J.E. Connexin26 in adult rodent central nervous system: demonstration at astrocytic gap junctions and colocalization with connexin30 and connexin43. J. Comp. Neurol. 4 (2001) 302-323
22. Lester S.C. Manual of Surgical Pathology. second ed. (2006), Churchill Livingstone 384 p
23. Lowenstein W.R. Junctional intercellular communication and the control of growth. Biochim. Biophys. Acta 560 (1979) 1-65
24. Laird D.W., Fistouris P., Batist G., Alpert L., Huynh H.T., Carystinos G.D., and Alaoui-Jamali M. Deficiency of connexin43 gap junctions is an independent marker for breast tumors. Cancer Res. 59 (1999) 4104-4110
25. Nicolson G.L., Dulski K.M., and Trosko J.E. Loss of intercellular junctional communication correlates with metastatic potential in mammary adenocarcinoma cells. Proc. Natl. Acad. Sci. 85 (1988) 473-476
26. Huang R.P., Fan Y., Hossain M.Z., Peng A., Zeng Z.L., and Boynton A.L. Reversion of the neoplastic phenotype of human glioblastoma cells by connexin 43 (cx43). Cancer Res. 58 (1998) 5089-5096
27. Pozzi A., Risek B., Kiang D.T., Gilula N.B., and Kumar N.M. Analysis of multiple gap junction gene products in the rodent and human mammary gland. Exp. Cell Res. 220 (1995) 212-219
28. Saunders M.M., Seraj M.J., Li Z., Zhou Z., Winter C.R., Welch D.R., and Donahue H.J. Breast cancer metastatic potential correlates with a breakdown in homospecific and heterospecific gap junctional intercellular communication. Cancer Res. 61 (2001) 1765-1767
29. Voordeckers M., Vinh-Hung V., Van de Steene J., Lamote J., and Storme G. The lymph node ratio as a prognostic factor in node-positive breast cancer. Radiother Oncol. 70 (2004) 225-230
30. Ranger G.S., and Mokbel K. The evolving role of sentinel lymph node biopsy for breast cancer. Eur. J. Surg. Oncol. 29 (2003) 423-425
31. Trifiro G., Viale G., Gentilini O., Travaini L.L., and Paganelli G. Sentinel node detection in pre-operative axillary staging. Eur. J. Nucl. Med. Mol. Imaging 31 Suppl. 1 (2004) S46-S55
32. Wieland A.W., Louwman M.W., Voogd A.C., van Beek M.W., Vreugdenhil G., and Roumen R.M. Determinants of prognosis in breast cancer patients with tumor involvement of the skin (pT4b). Breast J. 10 (2004) 123-128
33. Guerra I., Algorta J., Diaz de Otazu R., Pelayo A., and Farina J. Immunohistochemical prognostic index for breast cancer in young women. Mol. Pathol. 56 (2003) 323-327
34. Carter C., Allen C., and Henson D. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63 (1989) 181-187
35. Snelling J.D., Abdullah N., Brown G., King D.M., Moskovic E., and Gui G.P.H. Measurement of tumor size in case selection for breast cancer therapy by clinical assessment and ultrasound. Eur. J. Surg. Oncol. 30 (2004) 5-9
36. Catzeddu T., Bertelli G., Mastro L.D., and Venturini M. Sentinal lymph node biopsy in breast cancer patients: the medical oncology perspective. J. Surg. Oncol. 85 (2004) 129-132
37. Thomssen C., Janicke F., and Harbeck N. Clinical relevance of prognostic factors in axillary node-negative breast cancer. Onkologie 26 (2003) 438-445
38. Lane D.P. p53 the guardian of the genome. Nature 358 (1992) 15-16
39. Bray S.E., Schori C., and Hall P.A. The challenge of p53: linking biochemistry, biology and patient management. Stem Cells 16 (1998) 248-260
40. Ciocca D.R., and Elledge R. Molecular markers for predicting response to tamoxifen in breast cancer patients. Endocrine 13 (2000) 1-10
41. Jarvinen T.A.H., Pelto-Huikko M., Holli K., and Isola J. Estrogen receptor-beta is coexpressed with ER-alpha and PR and associated with nodal status, grade and proliferation rate in breast cancer. Am. J. Pathol. 156 (2002) 29-35
42. Chang C.C., Sun W., Cruz A., Saitoh M., Tai M.H., and Tosko J.E. A human breast epithelial cell type with stem cell characteristics as target cells for carcinogenesis. Radiat. Res. 155 (2001) 201-207
43. Saito T., Tanaka R., Wataba K., Kudo R., and Yamasaki H. Overexpression of estrogen receptor-alpha gene suppresses gap junctional intercellular communication in endometrial carcinoma cells. Oncogene 23 (2004) 1109-1116
44. Zhao K., Kuperman L., Geimonen E., and Andersen J. Progestin represses human connexin43 gene expression similarly in primary cultures of myometrial and uterine leiomyoma cells. Biol. Reprod. 54 (1996) 607-615
45. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu oncogene. Science 235 (1987) 177-182
46. Mograbi B., Corcelle E., Defamie N., Samson M., Nebout M., Segretain D., Fenichel P., and Pointis G. Aberrant connexin43 endocytosis by the carcinogen lindane involves activation of the ERK/mitogen-activated protein kinase pathway. Carcinogenesis 24 (2003) 1415-1423
47. Roberts P.C., Mottillo E.P., Baxa A.C., Heng H.H., Doyon-Reale N., Gregoire L., Lancaster W.D., Rabah R., and Schmelz E.M. Sequential molecular and cellular events during neoplastic progression: a mouse syngeneic ovarian cancer model. Neoplasia 7 (2005) 944-956